JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB257136

Human NDUFA13 (GRIM19) knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

NDUFA13 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon2 and 73 bp insertion in exon2 and 8 bp deletion in exon2.

View Alternative Names

2700054G14Rik, AU022060, B16.6, CDA016, CGI-39, CGI39 protein, CI-B16.6, Cell death regulatory protein, Cell death regulatory protein GRIM-19, Complex I-B16.6, FLJ58045, FLJ59191, Gene associated with retinoic and IFN-induced mortality 19 protein, Gene associated with retinoic and interferon-induced mortality 19 protein, Gene associated with retinoic interferon induced mortality 19 protein, NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13, NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13, NADH-ubiquinone oxidoreductase B16.6 subunit, NDUAD_HUMAN, NDUFA13, RGD1565358

5 Images
Western blot - Human NDUFA13 (GRIM19) knockout HeLa cell lysate (AB257136)
  • WB

Lab

Western blot - Human NDUFA13 (GRIM19) knockout HeLa cell lysate (AB257136)

Lane 1 : Wild-type HeLa cell lysate (20 ug)
Lane 2 : NDUFA13 knockout HeLa cell lysate (20 ug)
Lane 3 : Jurkat cell lysate (20 ug)

ab109017 was shown to specifically react with GRIM19 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab265863 (knockout cell lysate ab257136) was used. Wild-type and GRIM19 knockout samples were subjected to SDS-PAGE. ab109017 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4oC at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-GRIM19 antibody [EPR4471(2)] (<a href='/en-us/products/primary-antibodies/grim19-antibody-epr44712-ab109017'>ab109017</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

NDUFA13 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human NDUFA13 (GRIM19) knockout HeLa cell line (<a href='/en-us/products/cell-lines/human-ndufa13-grim19-knockout-hela-cell-line-ab265863'>ab265863</a>)

Lane 3:

Jurkat cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/10000 dilution

Predicted band size: 17 kDa

Observed band size: 17 kDa

false

Western blot - Human NDUFA13 (GRIM19) knockout HeLa cell lysate (AB257136)
  • WB

Lab

Western blot - Human NDUFA13 (GRIM19) knockout HeLa cell lysate (AB257136)

Lane 1 : Wild-type HeLa cell lysate (20 ug)
Lane 2 : NDUFA13 knockout HeLa cell lysate (20 ug)
Lane 3 : Jurkat cell lysate (20 ug)

ab110240 was shown to specifically react with GRIM19 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab265863 (knockout cell lysate ab257136) was used. Wild-type and GRIM19 knockout samples were subjected to SDS-PAGE. ab110240 and Anti-GAPDH antibody[EPR16891] - Loading Control (ab181602) were incubated overnight at 4oC at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (ab216777) and Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (ab216772) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-GRIM19 antibody [6E1BH7] (<a href='/en-us/products/primary-antibodies/grim19-antibody-6e1bh7-ab110240'>ab110240</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

NDUFA13 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human NDUFA13 (GRIM19) knockout HeLa cell line (<a href='/en-us/products/cell-lines/human-ndufa13-grim19-knockout-hela-cell-line-ab265863'>ab265863</a>)

Lane 3:

Jurkat cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-680rd-preadsorbed-ab216777'>ab216777</a>) at 1/10000 dilution

Predicted band size: 17 kDa,184 kDa,28 kDa,56 kDa,62 kDa,76 kDa

Observed band size: 17 kDa,184 kDa,29 kDa,56 kDa,70 kDa,75 kDa

false

Sanger Sequencing - Human NDUFA13 (GRIM19) knockout HeLa cell lysate (AB257136)
  • Sanger seq

Unknown

Sanger Sequencing - Human NDUFA13 (GRIM19) knockout HeLa cell lysate (AB257136)

Allele-2 : 2 bp deletion in exon2

Sanger Sequencing - Human NDUFA13 (GRIM19) knockout HeLa cell lysate (AB257136)
  • Sanger seq

Unknown

Sanger Sequencing - Human NDUFA13 (GRIM19) knockout HeLa cell lysate (AB257136)

Allele-3 : 73 bp insertion in exon2

Sanger Sequencing - Human NDUFA13 (GRIM19) knockout HeLa cell lysate (AB257136)
  • Sanger seq

Unknown

Sanger Sequencing - Human NDUFA13 (GRIM19) knockout HeLa cell lysate (AB257136)

Allele-1 : 8 bp deletion in exon2

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon2 and 73 bp insertion in exon2 and 8 bp deletion in exon2.

Disease

Adenocarcinoma

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

style
left-column

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab257136-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human NDUFA13 knockout HeLa cell lysate", "number":"AB257136-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB257136-CMP02", "productcode":"" } ] } } }
style
left-column

Properties and storage information

Gene name
NDUFA13
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

GRIM19 also known as NDUFA13 is a small protein with a molecular mass of approximately 16 kDa. It expresses mainly in mitochondria where it forms an integral component of the mitochondrial respiratory chain complex I. GRIM19 plays an important role in the functioning of complex I by facilitating the assembly and stabilization of the complex enabling efficient electron transport and ATP synthesis.
Biological function summary

GRIM19 interacts with several complexes and proteins within the mitochondrial inner membrane. As a part of complex I also known as NADH:ubiquinone oxidoreductase it contributes to the initial step of mitochondrial oxidative phosphorylation. GRIM19 also participates in the regulation of apoptosis and its expression is influenced during cellular stress situations highlighting its significance in cellular survival and energy production.

Pathways

GRIM19 integrates closely with mitochondrial apoptosis and energy metabolism pathways. Its interactions within oxidative phosphorylation place it in concert with both the electron transport chain and the apoptosis regulatory network. GRIM19 shares associations with related proteins such as cytochrome c oxidase and other complex I subunits highlighting its essential contribution to these important biological processes.

GRIM19 demonstrates links to various pathologies including cancer and mitochondrial diseases. Alterations in GRIM19 expression or function have been implicated in the progression of certain cancers such as colorectal and thyroid cancer where GRIM19's usual regulatory role in apoptosis can be disrupted. Additionally its involvement in mitochondrial disease connects to proteins like COX-A1 emphasizing the importance of maintaining functional complexes for cellular health.
style
left-column

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

style
left-column

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

style
left-column

Product protocols

style
left-column
style
left-column
style
right-column

Complementary Products

Primary Antibodies

AB110240

Anti-GRIM19 antibody [6E1BH7]

KO Validated

Immunocytochemistry/ Immunofluorescence - Anti-GRIM19 antibody [6E1BH7] (AB110240)

  • 4
  • 4
Proteins & Peptides

AB259412

Recombinant human VEGF 165A protein (Active)

Premium Bioactive

Mass Spectrometry - Recombinant human VEGF 165A protein (Active) (AB259412)

  • 0
  • 0
Proteins & Peptides

AB288799

Recombinant Human VCAM1 protein (Active)

Premium Bioactive

Biological Activity - Recombinant Human VCAM1 protein (Active) (AB288799)

  • 0
  • 0
Cell Lines & Lysates

AB265863

Human NDUFA13 (GRIM19) knockout HeLa cell line

Advanced Validation

Western blot - Human NDUFA13 (GRIM19) knockout HeLa cell line (AB265863)

  • 0
  • 0

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com